NNNN logo

ANBIO BIOTECHNOLOGY LTD

NNNNNASDAQ
🏆 #3485 by market capUS Equity
$6.16▲ $0.07 (+1.15%)
🌙 After hours$6.10▼ 0.97%Regular close · extended-hours price shown
🔔
Track NNNN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 1.3%
14d▲ 11.5%
30d▼ 15.5%
ytd▼ 79.2%
1y▼ 83.1%
🏦Market Cap
$270M
Small Cap
📈Revenue Growth (YoY)
+5.6%
Slowing
📊Gross Margin
86.1%
High
💵FCF Margin
—
⚖️P/S Ratio
22.7x
Expensive
Otter Score
64
Fair

Trading Snapshot

Day Range
$6.11 – $6.19
52-Week Range
$5.13 – $51.33
Volume
$3.44B
Avg Volume
$3.10B
Shares Outstanding
43.9M
Next Earnings
Oct 19, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$5M
P/E Ratio
31.5
P/S Ratio
22.7x
EPS (TTM)
$0.19
Dividend Yield
0.00%
Dilution (1yr)
+3.8%

Why Investors Own NNNN

  • ✓High-growth profile — revenue up +23.3% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 28% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NNNN logo

ANBIO BIOTECHNOLOGY LTD

NNNN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9M▲ +5.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
87.2%▲ +21.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$6M▲ +189.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$7M▼ −423.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
43.9M▲ +3.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▼ −$4M YoY
StockOtter · stockotter.space

About ANBIO BIOTECHNOLOGY LTD

Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia Pacific, North America, South America, and Africa. Their product range features various diagnostic solutions, including rapid antigen tests for SARS-CoV-2 (both individual and combined with influenza A/B). Anbio also develops and manufactures products leveraging advanced technologies like lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA), and reverse-transcription polymerase chain reaction (RT-PCR). These offerings cater to a wide array of markets, including over-the-counter sales, point-of-care testing, and traditional laboratory settings.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$6.18
▲ +0.3% Upside
High Target$6.74
Low Target$5.08
Based on 10 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

ANBIO BIOTECHNOLOGY LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift NNNN price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ANBIO BIOTECHNOLOGY LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.